Key result
Platelet-Activating Factor (PAF) is a key mediator in the thromboinflammatory processes of acute and long COVID-19, suggesting that PAF inhibitors could offer significant therapeutic benefits.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Smaragdi Antonopoulou (2025) conducted an editorial in COVID-19-induced cardiovascular complications. Platelet-Activating Factor (PAF) inhibitors was evaluated. Platelet-Activating Factor (PAF) is a key mediator in the thromboinflammatory processes of acute and long COVID-19, suggesting that PAF inhibitors could offer significant therapeutic benefits.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: